HIMS240927P14500
- 0.05
- 0.000.00%
Hims & Hers Health Newsroom
Hims & Hers Health, Inc. (HIMS) Rises Higher Than Market: Key Facts
Nivagen Pharmaceuticals Sells MedisourceRx Business Unit to Leading Health & Wellness Company
Form 144 | Hims & Hers Health(HIMS.US) Officer Proposes to Sell 11.63 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Sep 20, $Hims & Hers Health(HIMS.US)$ Officer Andrew Dudum intends to sell 687.5K shares of its common stock on Sep 20, with a total market value of approximately $11.63
Lilly Asks People Who Took Compounded Tirzepatide for Their Medical Records
Hims & Hers announced that they will offer a low stock price of the composite version Wegovy to specific professional groups in the USA.
Gelonghui September 19th | American remote medical services company Hims & Hers Health announced on Wednesday the launch of a new plan, offering a compounded version of Novo Nordisk's weight loss drug Wegovy at a discounted price of $99 per month to certain occupational patients. This pricing will be applicable to eligible US military personnel, teachers, nurses, police officers, firefighters, and veterans. According to its website, for patients participating in a 12-month treatment plan, the price of Semaglutide injectable solution is $199 per month. The company stated that the compounded GLP-1 injectable solution is developed by Hims &
Deep Dive Into Hims & Hers Health Stock: Analyst Perspectives (8 Ratings)
B of A Securities Maintains Buy on Hims & Hers Health, Lowers Price Target to $20
BofA Securities Maintains Hims & Hers Health(HIMS.US) With Buy Rating, Cuts Target Price to $20
BofA Securities analyst Allen Lutz maintains $Hims & Hers Health(HIMS.US)$ with a buy rating, and adjusts the target price from $24 to $20.According to TipRanks data, the analyst has a success rate
Noom Launches Cheaper Compounded Version of Novo's Semaglutide
Each U.S. State Has at Least 20% of Adults Living With Obesity: CDC
Novo Nordisk Reports Positive Results Of Weight-Loss Drug Liraglutide For Children As Young As 6, Eyes FDA And EMA Approval
Express News | Hims & Hers Health Inc Files for Mixed Shelf; Size Not Disclosed - SEC Filing
Hims & Hers Health, Inc.'s (NYSE:HIMS) Institutional Investors Lost 7.3% Over the Past Week but Have Profited From Longer-term Gains
Why Big Pharma Is Betting on Telehealth Strategies
Hims & Hers Health Insider Sold Shares Worth $4,844,924, According to a Recent SEC Filing
Hims & Hers Health(HIMS.US) 10% Shareholder Sells US$4.84 Million in Common Stock
$Hims & Hers Health(HIMS.US)$ 10% Shareholder Dudum Andrew sold 333.33K shares of common stock on Sep 3, 2024 at an average price of $14.5348 for a total value of $4.84 million.Source: Announcement
Battle Over Compounded Weight-Loss Medications - Sustainability and Regulation
MHRA Finds No Evidence Supporting Link Between GLP-1 Receptor Agonists And Suicidal Thoughts Or Actions; Will Continue Monitoring Risk Of Severe Psychiatric Reactions
Form 144 | Hims & Hers Health(HIMS.US) Officer Proposes to Sell 4.83 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Sep 3, $Hims & Hers Health(HIMS.US)$ Officer Andrew Dudum intends to sell 333.33K shares of its common stock on Sep 3, with a total market value of approximately $4.83 million.
Form 144 | Hims & Hers Health(HIMS.US) Officer Proposes to Sell 5.38 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Sep 3, $Hims & Hers Health(HIMS.US)$ Officer Oluyemi Okupe intends to sell 371.18K shares of its common stock on Sep 3, with a total market value of approximately $5.38